The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Toxicogenomics-Based Discrimination of Toxic Mechanism in HepG2 Human Hepatoma Cells
Abstract
The rapid discovery of sequence information from the Human Genome Project has exponentially increased the amount of data that can be retrieved from biomedical experiments. Gene expression profiling, through the use of microarray technology, is rapidly contributing to an improved understanding of global, coordinated cellular events in a variety of paradigms. In the field of toxicology, the potential application of toxicogenomics to indicate the toxicity of unknown compounds has been suggested but remains largely unsubstantiated to date. A major supposition of toxicogenomics is that global changes in the expression of individual mRNAs (i.e., the transcriptional responses of cells to toxicants) will be sufficiently distinct, robust, and reproducible to allow discrimination of toxicants from different classes. Definitive demonstration is still lacking for such specific "genetic fingerprints," as opposed to nonspecific general stress responses that may be indistinguishable between compounds and therefore not suitable as probes of toxic mechanisms. The present studies demonstrate a general application of toxicogenomics that distinguishes two mechanistically unrelated classes of toxicants (cytotoxic anti-inflammatory drugs and DNA-damaging agents) based solely upon a cluster-type analysis of genes differentially induced or repressed in cultured cells during exposure to these compounds. Initial comparisons of the expression patterns for 100 toxic compounds, using all approximately 250 genes on a DNA microarray ( approximately 2.5 million data points), failed to discriminate between toxicant classes. A major obstacle encountered in these studies was the lack of reproducible gene responses, presumably due to biological variability and technological limitations. Thus multiple replicate observations for the prototypical DNA damaging agent, cisplatin, and the non-steroidal anti-inflammatory drugs (NSAIDs) diflunisal and flufenamic acid were made, and a subset of genes yielding reproducible inductions/repressions was selected for comparison. Many of the "fingerprint genes" identified in these studies were consistent with previous observations reported in the literature (e. g., the well-characterized induction by cisplatin of p53-regulated transcripts such as p21(waf1/cip1) and PCNA [proliferating cell nuclear antigen]). These gene subsets not only discriminated among the three compounds in the learning set but also showed predictive value for the rest of the database ( approximately 100 compounds of various toxic mechanisms). Further refinement of the clustering strategy, using a computer-based optimization algorithm, yielded even better results and demonstrated that genes that ultimately best discriminated between DNA damage and NSAIDs were involved in such diverse processes as DNA repair, xenobiotic metabolism, transcriptional activation, structural maintenance, cell cycle control, signal transduction, and apoptosis. The determination of genes whose responses appropriately group and dissociate anti-inflammatory versus DNA-damaging agents provides an initial paradigm upon which to build for future, higher throughput-based identification of toxic compounds using gene expression patterns alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray
Schena, M., Shalon, D., Davis, R. W., & Brown, P. O. (1995) · Science · doi:10.1126/science.270.5235.467 · Cited by 9,609
The Bcl-2 Protein Family: Arbiters of Cell Survival
Adams, J. M., & Cory, S. (1998) · Science · doi:10.1126/science.281.5381.1322 · Cited by 5,332
Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale
DeRisi, J. L., Iyer, V. R., & Brown, P. O. (1997) · Science · doi:10.1126/science.278.5338.680 · Cited by 4,456
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
The Transcriptional Program in the Response of Human Fibroblasts to Serum
Iyer, V. R., Eisen, M. B., Ross, D. T., Schuler, G., Moore, T., Lee, J. C. F., Trent, J. M., Staudt, L. M., Hudson, J., Boguski, M. S., et al. (1999) · Science · doi:10.1126/science.283.5398.83 · Cited by 1,965
Accessing Genetic Information with High-Density DNA Arrays
Chee, M., Yang, R., Hubbell, E., Berno, A., Huang, X. C., Stern, D., Winkler, J., Lockhart, D. J., Morris, M. S., & Fodor, S. P. A. (1996) · Science · doi:10.1126/science.274.5287.610 · Cited by 1,489
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Yoshida, H., Haze, K., Yanagi, H., Yura, T., & Mori, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.50.33741 · Cited by 1,228
Clustering Gene Expression Patterns
Ben-Dor, A., Shamir, R., & Yakhini, Z. (1999) · Journal of Computational Biology · doi:10.1089/106652799318274 · Cited by 1,203
An Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183
Shalon, D., Smith, S. J., & Brown, P. O. (1996) · Genome Research · doi:10.1101/gr.6.7.639 · Cited by 1,115
Müller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., & Galle, P. R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119174 · Cited by 748
Microarrays and toxicology: The advent of toxicogenomics
Nuwaysir, E. F., Bittner, M., Trent, J., Barrett, J. C., & Afshari, C. A. (1999) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199903)24:3<153::aid-mc1>3.0.co;2-p · Cited by 666
Drug target validation and identification of secondary drug target effects using DNA microarrays
Marton, M. J., DeRisi, J. L., Bennett, H. A., Iyer, V. R., Meyer, M. R., Roberts, C. J., Stoughton, R., Burchard, J., Slade, D., Dai, H., et al. (1998) · Nature Medicine · doi:10.1038/3282 · Cited by 643
Shotgun Sequencing of the Human Genome
Venter, J. C., Adams, M. D., Sutton, G. G., Kerlavage, A. R., Smith, H. O., & Hunkapiller, M. (1998) · Science · doi:10.1126/science.280.5369.1540 · Cited by 353
Suzuki, A., Tsutomi, Y., Akahane, K., Araki, T., & Miura, M. (1998) · Oncogene · doi:10.1038/sj.onc.1202021 · Cited by 350
Afshari, C. A., Nuwaysir, E. F., & Barrett, J. C. (1999) · PubMed · Cited by 201
Simon, J. A., Szankasi, P., Nguyen, D. K., Ludlow, C. L., Dunstan, H. M., Roberts, C. J., Jensen, E. L., Hartwell, L. H., & Friend, S. H. (2000) · PubMed · Cited by 193
Endoplasmic Reticulum Stress Proteins Block Oxidant-induced Ca2+ Increases and Cell Death
Liu, H., Miller, E., van de Water, B., & Stevens, J. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.12858 · Cited by 190
p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells
Zamble, D. B., Jacks, T., & Lippard, S. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6163 · Cited by 149
Nehmé, A., Baskaran, R., Aebi, S. P., Fink, D. A., Nebel, S., Cenni, B., Wang, J. Y. J., Howell, S. B., & Christen, R. D. (1997) · PubMed · Cited by 129
Re‐expression of C/EBPα induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells
Jover, R., Bort, R., Gómez‐Lechón, M. J., & Castell, J. V. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00746-7 · Cited by 128
Wild-Type Human p53 Transactivates the Human Proliferating Cell Nuclear Antigen Promoter
Shivakumar, C. V., Brown, D. R., Deb, S., & Deb, S. P. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6785 · Cited by 120
Sun, X., Shimizu, H., & Yamamoto, K.-I. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4489 · Cited by 106
Lack of c‐Jun activity increases survival to cisplatin
Sánchez‐Pérez, I., & Perona, R. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00690-0 · Cited by 95
Molecular Genotoxicity Profiles of Apoptosis-Inducing Vanadocene Complexes
Aubrecht, J., Narla, R. K., Ghosh, P., Stanek, J., & Uckun, F. M. (1999) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1998.8592 · Cited by 77
Finally, the Book of Life and Instructions for Navigating It
Pennisi, E. (2000) · Science · doi:10.1126/science.288.5475.2304 · Cited by 76
The integration of microarray information in the drug development process
Braxton, S., & Bedilion, T. (1998) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(98)80144-4 · Cited by 64
NIH to Produce a 'Working Draft' of the Genome by 2001
Marshall, E. (1998) · Science · doi:10.1126/science.281.5384.1774 · Cited by 24
Cited by
Aardema, M. J., & MacGregor, J. T. (2002) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00292-5 · Cited by 389
Clustering of Hepatotoxins Based on Mechanism of Toxicity Using Gene Expression Profiles
Waring, J. F., Jolly, R. A., Ciurlionis, R., Lum, P. Y., Praestgaard, J. T., Morfitt, D. C., Buratto, B., Roberts, C., Schadt, E., & Ulrich, R. G. (2001) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2001.9243 · Cited by 376
Elucidating mechanisms of drug-induced toxicity
Liebler, D. C., & Guengerich, F. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1720 · Cited by 323
Boess, F. (2003) · Toxicological Sciences · doi:10.1093/toxsci/kfg064 · Cited by 306
Ganter, B., Tugendreich, S., Pearson, C. I., Ayanoglu, E., Baumhueter, S., Bostian, K. A., Brady, L., Browne, L. J., Calvin, J. T., Day, G.-J., et al. (2005) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2005.03.022 · Cited by 285
Metadata
- Authors
- Burczynski, M. E.
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-12-01
- Volume
- 58
- Issue
- 2
- Pages
- 399-415
- ISSN
- 1096-0929 (ISSN-L)
- OpenAlex
- W2141341794
- Cited by
- 253
- References
- 32
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.